Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies.

ABSTRACT:

Background

Disease burden in patients with peritoneal carcinomatosis (PC) is difficult to estimate. We evaluate whether peritoneal cell-free tumor DNA can be used as a measure of disease burden.

Patients and methods

Malignant ascites or peritoneal lavage fluids were collected from patients with PC under approved IRB protocol. Cell-free DNA was extracted from peritoneal fluid. Droplet digital PCR (ddPCR) was performed using a commercially available KRAS G12/G13 screening kit. Mutant allele frequency (MAF) was calculated based on the numbers of KRAS wild-type and mutant droplets. Clinicopathological, treatment and outcome data were abstracted and correlated with MAF of cell-free KRAS mutant DNA.

Results

Cell-free KRAS mutant DNA was detected in 15/37 (40%) malignant per

SUBMITTER: Leick KM 

PROVIDER: S-EPMC9731140 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature